[Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma]
[程序性死亡受体-1抑制剂治疗复发/难治性经典霍奇金淋巴瘤的疗效和安全性]
期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.issn.0253-2727.2023.07.005
Shan, D D; Liu, H M; Liu, W; Huang, W Y; Lyu, R; Deng, S H; Yi, S H; An, G; Xu, Y; Sui, W W; Wang, T Y; Fu, M W; Zhao, Y Z; Qiu, L G; Zou, D H